A New Chapter for LunaVax: Expanding Vaccine Access Through Innovation
At LunaVax, we believe no child should be left behind because of where they live.
Across the world, millions of children still lack access to life-saving vaccines — a gap we are determined to help close.
We’re excited to announce a major step forward in our journey:
Beginning this fall, LunaVax will participate in a pilot research collaboration connected with Harvard Medical School.
The pilot, launching in October 2025, will focus on evaluating the community-based delivery of microneedle vaccine patches for measles immunization in underserved regions of Nigeria. The study will assess feasibility, acceptance, and coverage compared to traditional needle-and-syringe methods. It will do so by partnering with local health workers, mobile immunization vans, and trusted community hubs.
If successful, this model could offer a scalable blueprint for expanding access to routine childhood vaccines across the continent.
This initiative focuses on exploring next-generation solutions to improve vaccine accessibility, including the use of microneedle vaccine patches and mobile immunization delivery models. Our goal is simple yet urgent:
Bring vaccines closer to the communities that need them most — faster, safer, and more equitably.
By combining local innovation with global expertise, LunaVax is committed to reimagining how vaccines reach underserved populations — starting with Nigeria and expanding across Africa.
Through this collaboration, we aim to unlock smarter immunization systems that can reshape the future of public health.
As we embark on this next chapter, we invite global health leaders, partners, funders, and innovators to join us. Together, we can rewrite the story of vaccine access — and build a healthier future for every child, everywhere.
Follow our journey on X @luna_vax and stay connected as we rewrite the story of vaccine access.
#BeLunacious